Abstract
Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system leading to demyelination and neurodegeneration of brain tissue. For a long time, research focused on T cells as the primary mechanism of disease. Driven by reports on the clinical results of B cell-depleting therapies, this therapeutic approach has come into focus in the last decade, and new highly effective treatments have been developed and are now complementing the therapeutic landscape. This review provides an overview of the development of B cell-depleting therapies and shows the advantages and disadvantages of current developments. In addition, we discuss basic considerations for CD20-depleted MS patients in the face of the COVID-19 pandemic.
Keywords: Autoimmunitiy; MRI; Neuroimmunology; Primary progressive multiple sclerosis; Relapsing-remitting multiple sclerosis.
【저자키워드】 MRI, Neuroimmunology, Relapsing-remitting multiple sclerosis., Primary progressive multiple sclerosis, Autoimmunitiy, 【초록키워드】 Treatment, therapy, multiple sclerosis, COVID-19 pandemic, T cell, therapeutic, Research, Patient, Central nervous system, disease, neurodegeneration, Therapies, Demyelination, Therapeutic approach, disadvantage, primary mechanism, Multiple, chronic inflammatory disease, brain tissue, effective, addition, provide, 【제목키워드】 therapy, Trial, multiple sclerosis, Evidence,